Senores Pharmaceuticals Ltd
NSE: SENORES | BSE: 544319
₹1,113.00
As on 21-May-2026 10:24IST
Market cap
₹4,987 Cr
Revenue (TTM)
₹650 Cr
P/E Ratio
43.2
P/B Ratio
5.3
Div. Yield
0 %
Quality Score
1/10
Growth Score
3/10
Valuation Score
3/10
Momentum Score
10/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹115 Cr
-
ROE
11.8 %
-
ROCE
11.9 %
-
Industry P/E
37.35
-
EV/EBITDA
23.9
-
Debt to Equity
0.2
-
Book Value
₹202.7
-
EPS
₹25.1
-
Face value
10
-
Shares outstanding
46,053,588
Years Aggregate
CFO
₹--
EBITDA
₹--
Net Profit
₹--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Senores Pharmaceuticals
| 35.4 | 22.0 | 37.4 | 121.1 | -- | -- | -- |
|
BSE Healthcare
| 10.1 | 10.3 | 11.0 | 13.3 | 28.0 | 14.4 | 12.1 |
|
Company
|
2025
|
|---|---|
|
Senores Pharmaceuticals
| 43.9 |
|
BSE Small Cap
| -6.6 |
|
BSE Healthcare
| -3.3 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Senores Pharmaceuticals
|
1,113.0 | 4,987.4 | 649.5 | 121.6 | 23.7 | 13.2 | 43.2 | 5.3 |
| 1,069.5 | 13,003.0 | 2,551.8 | 564.5 | 28.3 | 18.4 | 23 | 3.9 | |
| 443.7 | 7,588.3 | 1,053.1 | 293.6 | 32.3 | 24.6 | 25.8 | 5.9 | |
| 1,124.0 | 11,670.5 | 1,158.7 | 309.6 | 31.9 | 17.3 | 37.3 | 6.2 | |
| 1,722.7 | 32,846.4 | 9,203.5 | 941.3 | 15.4 | 19.6 | 35.5 | 6.6 | |
| 356.6 | 3,883.5 | 159.3 | 47.8 | 39.0 | 18.6 | 81.3 | 14.0 | |
| 16,634.0 | 21,331.6 | 2,023.0 | 364.0 | 23.9 | 20.8 | 58.6 | 11.4 | |
| 2,300.2 | 3,808.9 | 707.5 | 115.2 | 17.8 | 19.4 | 33.1 | -- | |
| 666.0 | 7,341.7 | 502.0 | 138.7 | -- | 32.8 | 52.9 | 8.5 | |
| 272.0 | 7,090.1 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 12.0 |
Shareholding Pattern
View DetailsNews & Analysis
All News
Senores Pharmaceuticals IPO analysis
5 min read•By Satyajit Sen
About Senores Pharmaceuticals
--
-
Incorporated
2017
-
Chairman
Sanjay Shaileshbhai Majmudar
-
Managing Director
Swapnil Jatinbhai Shah
-
Headquarters
Ahmedabad, Gujarat
-
Website
Looking for more details about Senores Pharmaceuticals Ltd’s IPO? Explore our IPO Details page.
Quarterly Updates
Annual Reports
FAQs for Senores Pharmaceuticals
What is the current share price of Senores Pharmaceuticals Ltd Today?
The share price of Senores Pharmaceuticals Ltd is ₹1,113.00 (NSE) and ₹1,110.35 (BSE) as of 21-May-2026 10:24 IST. Senores Pharmaceuticals Ltd has given a return of 121.14% in the last 1 years.
What is the current PB & PE ratio of Senores Pharmaceuticals Ltd?
The P/E ratio of Senores Pharmaceuticals Ltd is 43.23 times as on 20-May-2026, a 16 premium to its peers’ median range of 37.35 times.
The P/B ratio of Senores Pharmaceuticals Ltd is 5.34 times as on 20-May-2026, a 126 premium to its peers’ median range of 2.36 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
45.04
|
3.35
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2025
|
45.04
|
3.35
|
What is the 52 Week High and Low of Senores Pharmaceuticals Ltd?
The 52-week high and low of Senores Pharmaceuticals Ltd are Rs 1,194.40 and Rs 499.55 as of 21-May-2026.
What is the market cap of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd has a market capitalisation of ₹ 4,987 Cr as on 20-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Senores Pharmaceuticals Ltd?
Before investing in Senores Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.